TriSalus Life Sciences

TriSalus Life Sciences is a public, clinical-stage biotech focused on overcoming the anatomical and biological barriers that render liver and pancreatic tumors resistant to treatment. Its core strategy integrates two proprietary components: the Pressure-Enabled Drug Delivery (PEDD™) method, which uses FDA-cleared catheter devices to enhance intravascular drug delivery, and nelitolimod (SD-101), a TLR9 agonist designed to reprogram the immunosuppressive tumor microenvironment. The company is advancing multiple Phase 1/2 trials, aiming to validate its platform and create new standards of care for some of oncology's most challenging solid tumors.

Integrated platform combining the Pressure-Enabled Drug Delivery (PEDD™) method—using proprietary catheter systems to overcome intratumoral pressure—with nelitolimod (SD-101), a TLR9 agonist designed to reverse immunosuppression in the tumor microenvironment.